Article in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Marianna PirasUnit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland. Marianna.piras@chuv.ch.ORCID 0009-0001-5579-0199
Jue LinDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.
Marie Catherine SadlerUniversity Center for Primary Care and Public Health, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2599-9207
Setareh RanjbarPsychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland.ORCID 0000-0002-0238-2976
Claire GrosuUnit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland.
Nermine LaaboubUnit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland.
Martin PreisigPsychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland.ORCID 0000-0001-5689-4259
Franziska GammaLes Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland.
Kerstin Jessica PlessenService of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland.
Armin von GuntenService of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland.ORCID 0000-0001-7852-3803
Philippe ConusService of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland.
Zoltan KutalikUniversity Center for Primary Care and Public Health, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-8285-7523
Chin B EapUnit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Prilly, Switzerland. chinbin.eap@unil.ch.ORCID 0000-0002-5439-0230
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Weight-inducing psychotropic treatments are risk factors for age-related diseases such as cardiovascular disorders, which are associated with both inflammation and telomere length shortening. With a longitudinal design, the present study evaluates telomere length trajectories after 1 year of weight-inducing psychotropic medication, accounting for weight changes and the inflammatory biomarker high-sensitivity C-Reactive Protein (CRP). Among 200 patients, an overall median telomere shortening of -41.2 bp was observed (p = 0.014), which is comparable with the general population's yearly telomere attrition. Linear regression showed on average -93.1 and -58.9 bp of further telomere shortening per five units of BMI for BMI values < or ≥30 kg/m
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Psychotropic-induced weight gain and telomere length: results from a one-year longitudinal study and a large population-based cohort. · full record | OpenQuestion